Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3018% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics cash
Cash and short-term investments held at the end of each period.
Gyre Therapeutics's cash was $57.42M at Sep 30, 2026. For fiscal 2025 it was $64.55M, up 142.0% from the year before. Over ten years it grew 7.1% a year on average. The highest annual figure on record is $214.02M in fiscal 2010.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $64.55M | +142.0% |
| FY2024 | Dec 31, 2024 | $26.67M | -20.4% |
| FY2023 | Dec 31, 2023 | $33.50M | +54.4% |
| FY2022 | Dec 31, 2022 | $21.70M | -53.7% |
| FY2021 | Dec 31, 2021 | $46.90M | -42.7% |
| FY2020 | Dec 31, 2020 | $81.90M | +6.5% |
| FY2019 | Dec 31, 2019 | $76.90M | -36.0% |
| FY2018 | Dec 31, 2018 | $120.10M | +270.7% |
| FY2017 | Dec 31, 2017 | $32.40M | +89.5% |
| FY2016 | Dec 31, 2016 | $17.10M | -47.4% |
| FY2015 | Dec 31, 2015 | $32.50M | -38.1% |
| FY2014 | Dec 31, 2014 | $52.50M | +29.1% |
| FY2013 | Dec 31, 2013 | $40.67M | -11.8% |
| FY2012 | Dec 31, 2012 | $46.12M | -76.3% |
| FY2011 | Dec 31, 2011 | $195.00M | -8.9% |
| FY2010 | Dec 31, 2010 | $214.02M | +155.1% |
| FY2009 | Dec 31, 2009 | $83.91M | +63.9% |
| FY2008 | Dec 31, 2008 | $51.20M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $57.42M | -4.4% |
| Q2 FY2026 | Jun 30, 2026 | $57.35M | +5.5% |
| Q1 FY2026 | Mar 31, 2026 | $49.81M | +66.6% |
| Q4 FY2025 | Dec 31, 2025 | $64.55M | +142.0% |
| Q3 FY2025 | Sep 30, 2025 | $60.05M | +139.3% |
| Q2 FY2025 | Jun 30, 2025 | $54.37M | +116.6% |
| Q1 FY2025 | Mar 31, 2025 | $29.89M | -20.0% |
| Q4 FY2024 | Dec 31, 2024 | $26.67M | -20.4% |
| Q3 FY2024 | Sep 30, 2024 | $25.09M | +1026.2% |
| Q2 FY2024 | Jun 30, 2024 | $25.10M | +262.6% |
| Q1 FY2024 | Mar 31, 2024 | $37.35M | +361.2% |
| Q4 FY2023 | Dec 31, 2023 | $33.50M | +54.4% |
| Q3 FY2023 | Sep 30, 2023 | $2.23M | -90.4% |
| Q2 FY2023 | Jun 30, 2023 | $6.92M | -90.8% |
| Q1 FY2023 | Mar 31, 2023 | $8.10M | -76.7% |
| Q4 FY2022 | Dec 31, 2022 | $21.70M | -53.7% |
| Q3 FY2022 | Sep 30, 2022 | $23.09M | -64.2% |
| Q2 FY2022 | Jun 30, 2022 | $75.39M | -12.8% |
| Q1 FY2022 | Mar 31, 2022 | $34.82M | -67.5% |
| Q4 FY2021 | Dec 31, 2021 | $46.90M | -42.7% |
| Q3 FY2021 | Sep 30, 2021 | $64.50M | -38.0% |
| Q2 FY2021 | Jun 30, 2021 | $86.50M | -26.3% |
| Q1 FY2021 | Mar 31, 2021 | $107.00M | +2.4% |
| Q4 FY2020 | Dec 31, 2020 | $81.90M | +6.5% |
| Q3 FY2020 | Sep 30, 2020 | $104.10M | +22.5% |
| Q2 FY2020 | Jun 30, 2020 | $117.40M | +24.9% |
| Q1 FY2020 | Mar 31, 2020 | $104.50M | -0.8% |
| Q4 FY2019 | Dec 31, 2019 | $76.90M | -36.0% |
| Q3 FY2019 | Sep 30, 2019 | $85.00M | -34.2% |
| Q2 FY2019 | Jun 30, 2019 | $94.00M | -31.0% |
| Q1 FY2019 | Mar 31, 2019 | $105.30M | -26.6% |
| Q4 FY2018 | Dec 31, 2018 | $120.10M | +270.7% |
| Q3 FY2018 | Sep 30, 2018 | $129.22M | +370.8% |
| Q2 FY2018 | Jun 30, 2018 | $136.15M | +320.4% |
| Q1 FY2018 | Mar 31, 2018 | $143.52M | +887.5% |
| Q4 FY2017 | Dec 31, 2017 | $32.40M | +89.5% |
| Q3 FY2017 | Sep 30, 2017 | $27.45M | – |
| Q2 FY2017 | Jun 30, 2017 | $32.39M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.53M | – |
| Q4 FY2016 | Dec 31, 2016 | $17.10M | – |
See a number that looks wrong?